Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide - PubMed
12 hours ago
- #tirzepatide
- #obesity
- #semaglutide
- Study examines obesity treatments and weight changes after discontinuing semaglutide or tirzepatide.
- Retrospective cohort study using electronic health records from 2021 to 2025 in Ohio and Florida.
- 7938 patients included, with mean age 55.7 years; 63.8% female.
- 19.6% restarted the original medication, 35.2% received alternative treatments post-discontinuation.
- Mean weight change: -8.4% (obesity) and -4.4% (T2D) from baseline to discontinuation.
- Post-discontinuation weight change: +0.5% (obesity) and -1.3% (T2D) after one year.
- Significant individual variability observed in weight changes post-discontinuation.